Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;69(3):e14578.
doi: 10.1111/aas.14578.

The adverse effects with ibuprofen after major orthopedic surgeries: A protocol for the PERISAFE randomized clinical trial

Affiliations

The adverse effects with ibuprofen after major orthopedic surgeries: A protocol for the PERISAFE randomized clinical trial

Christina Cleveland Westerdahl Laursen et al. Acta Anaesthesiol Scand. 2025 Mar.

Abstract

Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for pain treatment after elective hip and knee arthroplasties. However, evidence regarding the incidence of adverse effects with short-term NSAID treatment following surgery is limited. We, therefore, aim to assess the adverse effects with an eight-day postoperative treatment with ibuprofen after elective hip and knee arthroplasties.

Methods and analysis: PERISAFE is a randomized, placebo-controlled, blinded multicenter trial with 90-day and one-year follow-up. Eligible patients undergoing elective hip or knee arthroplasty are allocated 1:1 to either ibuprofen 400 mg ×3/day or identical placebo ×3/day for eight days after surgery. The primary outcome is a composite of either death, acute myocardial infarction, stroke, pulmonary embolism, deep venous thrombosis, renal failure, major bleeding, re-operation, gastrointestinal ulcer, or readmission within 90 days postoperatively. Secondary outcomes are hospital-free days within 90 days postoperatively, a composite of ibuprofen and opioid-related adverse reactions based on eight-day postoperative diary, and health related quality of life after 90 days postoperatively. A total of 2904 patients are needed to demonstrate a relative risk reduction of 33% in the placebo group, accepting a risk of type I error of 5% and type II error of 20% and a proportion of serious adverse events in the ibuprofen group of 8%. The primary analysis will be in the modified intention-to-treat population.

Ethics and dissemination: The trial is approved by the Danish Medicine Agency and the Research Ethics Committee (EU CT no. 2022-502, 502-32-00). We plan to submit for publication in a major international peer-reviewed journal and present results at scientific meetings.

Keywords: adverse effects; analgesic treatment; arthroplasty; hip arthroplasty; ibuprofen; knee arthroplasty; nsaid; pain treatment; total hip arthroplasty surgery; total knee arthroplasty surgery; unicompartment knee arthroplasty.

PubMed Disclaimer

References

REFERENCES

    1. Ethgen O, Bruyère O, Richy F, Dardennes C, Reginster JY. Health‐related quality of life in Total hip and Total knee arthroplasty. J Bone Jt Surg Am. 2004;86(5):963‐974.
    1. Rupp M, Lau E, Kurtz SM, Alt V. Projections of primary TKA and THA in Germany from 2016 through 2040. Clin Orthop Relat Res. 2020;478(7):1622‐1633.
    1. Inacio MCS, Graves SE, Pratt NL, Roughead EE, Nemes S. Increase in Total joint arthroplasty projected from 2014 to 2046 in Australia: a conservative local model with international implications. Clin Orthop Relat Res. 2017;475(8):2130‐2137.
    1. Sloan M, Premkumar A, Sheth NP. Projected volume of primary Total joint arthroplasty in the U.S., 2014 to 2030. J Bone Jt Surg Am. 2018;100(17):1455‐1460.
    1. Singh JA, Lewallen DG. Ninety‐day mortality in patients undergoing elective Total hip or Total knee arthroplasty. J Arthroplast. 2012;27(8):1417‐1422.

Publication types

Substances

LinkOut - more resources